2101 Cottontail Lane Somerset, NJ 08873 |
VIA EDGAR |
June 2, 2020
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 4546
Washington, D.C. 20549
Attn: | Ms. Jenn Do |
Ms. Lisa Vanjoske
Mr. Jeffrey Gabor
Ms. Celeste Murphy
Re: | Legend Biotech Corporation |
Registration Statement on Form F-1
File No. 333-238232
Acceleration Request
Requested Date: Thursday, June 4, 2020
Requested Time: 4:00 P.M. Eastern Daylight Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the Registrant) hereby requests that the Securities and Exchange Commission (the Commission) take appropriate action to cause the above-referenced Registration Statement on Form F-1 (File No. 333-238232) (the Registration Statement) to become effective on June 4, 2020, at 4:00 p.m., Eastern Daylight Time, or as soon thereafter as is practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff (the Staff).
Once the Registration Statement has been declared effective, please orally confirm that event with Divakar Gupta of Cooley LLP (212) 479-6474, counsel to the Registrant, Robert W. Phillips at (415) 693-2020 or Mark Ballantyne at (703) 456-8084.
Very truly yours, | ||
Legend Biotech Corporation | ||
By: | /s/ Yuan Xu | |
Yuan Xu | ||
Chief Executive Officer |
cc: | Yuan Xu, Ph.D., Legend Biotech Corporation |
Ying Huang, Ph.D., Legend Biotech Corporation
Robert W. Phillips, Cooley LLP
Richard C. Segal, Cooley LLP
Mark Ballantyne, Cooley LLP
Richard D. Truesdell, Jr., Davis Polk & Wardwell LLP
Yasin Keshvargar, Davis Polk & Wardwell LLP